Murray Sarah
Department of Clinical Nursing, University of Sydney, NSW.
Aust Crit Care. 2002 May;15(2):51-63. doi: 10.1016/s1036-7314(02)80006-6.
Patients in acute respiratory failure (ARF) frequently present to the emergency department (ED). Traditionally management has involved mechanical ventilation via endotracheal intubation. Such invasive forms of treatment, however, correlate with a higher incidence of infection, mortality, length of stay and contribute to the costs of intensive care. Non-invasive positive pressure ventilation (NIPPV) such as bi-level positive airway pressure (BiPAP) may therefore provide an alternative and preferable form of treatment. Whilst contemporary literature supports the use of BiPAP in hypercapnic ARF, its role in acute hypoxaemic presentations remains elusive. Specifically, the efficacy and safety of BiPAP in the treatment of acute cardiogenic pulmonary oedema (ACPO) remains a contentious issue. The aim of this paper is to explore the physiological rationale for treatment of ACPO with BiPAP. Particular attention will focus on the comparative theoretical advantages of BiPAP in relation to continuous positive airway pressure (CPAP), and a review of recent research. Discussion will incorporate timeliness in the application of BiPAP, indicators of successful treatment, appropriate manipulation of pressure settings, nursing workload and management of patients beyond the ED. Whilst the theoretical advantages of BiPAP ventilation are acknowledged, larger randomised controlled research studies are recommended in order to clearly ensure its safe and effective application in the treatment of ACPO.
急性呼吸衰竭(ARF)患者常被送往急诊科(ED)。传统的治疗方法是通过气管插管进行机械通气。然而,这种侵入性治疗方式与感染发生率更高、死亡率更高、住院时间更长相关,且增加了重症监护的成本。因此,无创正压通气(NIPPV),如双水平气道正压通气(BiPAP),可能提供一种替代且更优的治疗方式。虽然当代文献支持在高碳酸血症性ARF中使用BiPAP,但其在急性低氧血症表现中的作用仍不明确。具体而言,BiPAP治疗急性心源性肺水肿(ACPO)的疗效和安全性仍是一个有争议的问题。本文旨在探讨用BiPAP治疗ACPO的生理原理。特别关注BiPAP相对于持续气道正压通气(CPAP)的比较理论优势,以及对近期研究的综述。讨论将包括BiPAP应用的及时性、成功治疗的指标、压力设置的适当调整、护理工作量以及急诊科以外患者的管理。虽然BiPAP通气的理论优势得到认可,但建议进行更大规模的随机对照研究,以明确确保其在ACPO治疗中的安全有效应用。